AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06782685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Exploration started with 60mg/m\^2 dose, preset 60mg/m\^2, 85mg/m\^2, 2 dose groups, IV infusion, d1
Study NCT06782685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5mg/kg，i.v.，d1
Study NCT06782685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400mg/m\^2, i.v.，46h
Study NCT06782685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV
Description: 400mg/m\^2, i.v.，d1
Study NCT06782685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Liposomal
Description: 70mg/m\^2, i.v.，d1
Study NCT06782685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal
Description: Phase II recommended dose
Study NCT06782685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Phase II recommended dose
Study NCT06784778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PBMC Kinase Activity Profile
Description: Kinase activity profile will be correlated to the observed clinical outcome parameters (including survival and toxicity associated with the therapy) of standard of care treatments
Study NCT06785311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Native Spirit After-School Program
Description: Native Spirit is a culturally-grounded after-school program that is community-specific. The program is 10-sessions/weeks long and each session is 1.5-2 hours in duration. Each session is guided by a local cultural knowledge holder and is focused on a different cultural value and accompanying cultural practice. Native Spirit aims to promote self-esteem, cultural efficacy, awareness of cultural connectedness, and resilience while preventing and/or slow down the initiation of substance use.
Study NCT06785311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Native Spirit After-School Program
Description: Native Spirit is a culturally-grounded after-school program that is community-specific. The program is 10-sessions/weeks long and each session is 1.5-2 hours in duration. Each session is guided by a local cultural knowledge holder and is focused on a different cultural value and accompanying cultural practice. Native Spirit aims to promote self-esteem, cultural efficacy, awareness of cultural connectedness, and resilience while preventing and/or slow down the initiation of substance use.
Study NCT06787833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: to complete a questionnaire including socio-demographic data, Perceived Stress Scale (PSS-14), and Coronavirus Anxiety Scale (CAS) before patient admission (T1). The students were asked to complete the same questionnaire at the end of the day after working for 2 days (T2) and in the morning on the 5th day of their study before seeing patients (T3).The same questionnaire was refilled at the end of the week in which music was played (T4).
Study NCT06787833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music
Description: Each of the students participating in the study was given disposable headphones every day during the week of music listening. In this study, Beethoven's Moonlight Sonata (1 hour 2 minutes)23,55, Mozart's Serenata Notturna KV239 (12.50 minutes)18,19, and Pachelbel's Canon in D major (6.16 minutes)24,25 were used. It was shared with the students via WhatsApp and they were allowed to listen to this music on their phones for 1 week (2 hours on average) during the study period.
Study NCT06357182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT06357182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06357182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06357182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06357182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: Given PO
Study NCT06357182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06357182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary study
Study NCT06357182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06552234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Repotrectinib 160 mg BID, until progression or unacceptable toxicity
Study NCT04685577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
Study NCT04685577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle)
Description: Participants will receive vehicle with out the investigational product
Study NCT05738486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV
Study NCT05738486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV
Study NCT05607719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevespi
Description: Two puffs twice a day
Study NCT05607719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bretzri
Description: Two puffs twice a day
Study NCT06358755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocus Incorporated Multiple Segments lenses
Description: Defocus Incorporated Multiple Segments lenses that provide optical defocus for myopia control will be given to this group of participants.
Study NCT06358755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single vision spectacle lenses
Description: Single vision spectacle lenses will be given to this group of participants.
Study NCT06358755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose atropine
Description: 0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
Study NCT06111898 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study NCT05643729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofin
Description: Intravenous Infusion (IV) of Zofin
Study NCT05643729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Infusion of sterile saline
Study NCT05097287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: solution for injection subcutaneous
Study NCT05097287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for injection subcutaneous
Study NCT06784479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam and Propofol
Description: Application of Remimazolam and Propofol to induce sleep
Study NCT06784479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Application of Propofol to induce sleep
Study NCT06784479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and propofol
Description: Application of Midazolam and Propofol to induce sleep
Study NCT06785584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: receive neoadjuvant treatment with ensartinib 225 mg once a day, po. for 2 consecutive cycles (56 days) to evaluate possibility of surgery, or discontinue the treatment because of disease recurrence or intolerable toxicity
Study NCT06787664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06787404 — intervention group
Intervention type: DRUG
Intervention: Ephedrine
Description: 5 milligrams of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
Study NCT06787404 — intervention group
Intervention type: DRUG
Intervention: Noradrenalin
Description: 5 micrograms of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
Study NCT06787482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ACE Retino
Description: 1 ml sublingually self administer / 4 times/day for 6 months
Study NCT06787482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACE Retino
Description: 1 ml sublingually self administer / 4 times/day for 6 months
Study NCT06787482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACE Retino
Description: 1 ml sublingually 4 times daily for 6 months
Study NCT05509998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Method (SM)
Description: All consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate.
Study NCT06785532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Responsive Neurostimulation (RNS)
Description: The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
Study NCT06785012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-89495120
Description: JNJ-89495120 will be administered.
Study NCT06785012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT06785558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic therapy
Description: Overactive bladder group use anticholinergic drug and 1 month later their urinary atp levels calculated again
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 150 mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg FHND1002（fasting）
Description: Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 200 mg FHND1002（fasting）
Description: Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 250mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250mg FHND1002
Description: Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 200mg FHND1002(postprandial)
Description: Participants will receive a one-time dose (200 mg) under postprandial conditions
Study NCT06782958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg FHND1002(postprandial)
Description: Participants will receive a one-time dose (200 mg) under postprandial conditions
Study NCT06783517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cerabone
Description: Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone graft (cerabone®,Botiss biomaterial) will be added to the implant
Study NCT06783517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cerabone®plus
Description: Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone substitute with sodium hyaluronate graft (cerabone®plus,Botiss biomaterial) will be added to the implant
Study NCT06785545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CA19-9
Description: All patients Ca19-9 levels calculated from their urinary samples
Study NCT06780592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebreltinib + Temozolomide
Description: Vebreltinib is a capsule in the form of 25 mg and 100mg, twice daily. Participants received Vebreltinib (300 mg Bid) in combination with Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
Study NCT06780592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Participants received Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
Study NCT06783608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). Patients were asked to measure and record their blood glucose value before breakfast. The yoga session was started 30 minutes after breakfast, and after the session was completed, they were asked to measure and record their blood glucose value again at 120 minutes after breakfast.
Study NCT06782750 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy
Description: Traditional physiotherapy treatment was applied 5 days in a week, 1 hour in a day for 6 weeks.
Study NCT06784050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Balanced Occlusion
Description: Dentures designed under this scheme feature a fully bilateral balanced articulation, ensuring bilateral, simultaneous contact of the anterior and posterior denture teeth in both centric and eccentric positions. This occlusal scheme is aimed at promoting stability and functionality of the dentures during various mandibular movements.
Study NCT06784050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monoplane Occlusion
Description: This scheme utilizes zero-degree teeth to create a flat occlusal plane, which is designed to simplify the occlusal contacts and minimize the transmission of lateral forces during mastication. The aim is to improve masticatory efficiency by reducing the complexity of tooth contact
Study NCT05509998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and Communication Method (SCM)
Description: Clinicians will be trained to discuss findings and provide referrals using the ComPsych model. ComPsych prepares clinicians to effectively communicate diagnostic, prognostic and treatment information about FEP and CHR with patients and families, using a model that instils realistic hope and provides information effectively to encourage shared decision making about treatment. All consecutive patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Following the evaluation, the clinician will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty services, as appropriate.
Study NCT06608095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypothermia group
Description: Minimize the temperature of the thermometric tank or thermometric catheter for rapid temperature control. Use a thermometric catheter to monitor changes in the patient's core body temperature in real time. When the core body temperature drops to 34 ℃, adjust the target temperature of the temperature-controlled water tank to 34 ℃ and adjust the target temperature of the temperature-controlled water tank in real time according to the patient's core body temperature. Keep the core body temperature around 34 ℃. Maintain the body temperature at 34℃ for at least 24 hours after the patient resumes autonomous circulation. After the patient has resumed voluntary circulation for 24 hours, the rewarming process can begin. The target temperature of the temperature control tank will increase at a rate of 0.2°C/h. After reaching 36°C, maintain the current temperature. Once 36°C is reached, the current temperature is maintained until autonomic circulation has been restored for 5 days.
Study NCT06608095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normothermia group
Description: Set the temperature of the temperature-controlled water tank or the in vivo cooling catheter to 37°C to maintain the patient's core temperature between 36.5-37.5°C. Real-time monitoring of the patient's core temperature changes through the thermometric urinary catheter, and real-time adjustment of the temperature of the temperature-controlled water tank. The patient's temperature was maintained between 36.5-37.5°C after the patient resumed voluntary circulation until the end of temperature control 5 days after the recovery of voluntary circulation.
Study NCT06608017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine granules
Description: Treatment group
Study NCT06608017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-controlled group
Study NCT04729751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~* 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~* 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base
Study NCT06612684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezoelectric syndesmotomy
Description: Syndesmotomy, the first phase of tooth extraction, will be provided by a piezoelectric device instead of manual instruments.
Study NCT06612047 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate biopsy
Description: All patients were required to underwent transperineal prostate biopsy (Systemetic + Targeted) and have corresponding pathological diagnosis results.
Study NCT05542251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Educational Program
Description: The intervention is a series of 9 educational modules delivered via social media that will teach participants: 1) principles of infant learning, 2) principles of infant motor learning, and 3) principles of positive parenting.